Exhibit B on the 8K "d. The strategies for t
Post# of 30028
"d. The strategies for the AMBS, AVDX and Cutanogen will only be implemented upon the signing of the LOI and the cooperative support of the secured debt holders. Funding would be pursued immediately following the signing of the LOI. Successful funding for any of the two entities at the following levels would trigger the unconditional release of all assets of AMBS by the debt holders: $2.5 million for Cutanogen, $1.5 million for AVDX, or $1.5 million for AMBS, accompanied by an asset injected by SED Biomedical into AMBS that is valued by a nationally recognized firm at a minimum of $12.5 million. "